New Primary Aldosteronism Guidelines – Endocrine Society 2025; Episode 3 of 4

This episode reviews medications and hormonal therapies that can falsely raise the Aldosterone-to-Renin Ratio (ARR), creating false-positive results in primary aldosteronism screening. • Covers centrally acting alpha-2 agonists, beta blockers, NSAIDs, and combined estrogen-progestin therapy. • Explains mechanisms for PAC and renin changes, highlighting discordance between PRA vs DRC assays. • Reviews practical withdrawal timelines (minimal vs full) to reduce confounding before ARR testing.

There are no comments yet.

Please log in to write the first comment.